Please assess the completion status of the following clinical trial:

Trial Title: ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of histo or cytopathology confirmed, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).~* It is acceptable for subjects with the presence of the exon 20 T790M mutation together with either EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21) to be included in this study~* No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Minimum of 12 months disease free interval between completion of neoadjuvant/adjuvant systemic therapy and recurrence of NSCLC~* Adequate tissue sample must be available for central analyses.~* Adequate renal, hematologic, liver function.~* ECOG PS of 0-1.~* Radiologically measurable disease.~Exclusion Criteria:~* Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.~* Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation.~* Any history of brain metastases or leptomeningeal metastases.~* Any previous anti-cancer systemic treatment of early, locally advanced, or metastatic NSCLC.~* Any surgery(not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments~* Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug.~* Current enrollment in another therapeutic clinical study.~* History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease~* Uncontrolled medical disorders.~* Prior malignancy and concurrent malignancy except for non melanoma skin cancer or in-situ cervical cancer with no evidence of active disease.~* Use of narrow therapeutic index drugs that are CYP2D6 substrates from screening to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Dacomitinib (PF-00299804) (Type: EXPERIMENTAL): Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
- gefitinib (Type: ACTIVE_COMPARATOR): Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).